MaxCyte Inc (LON:MXCT)‘s stock had its “buy” rating reaffirmed by analysts at Panmure Gordon in a research report issued to clients and investors on Tuesday. They currently have a GBX 170 ($2.22) price target on the stock. Panmure Gordon’s price target would suggest a potential upside of 101.18% from the company’s previous close.

MaxCyte (LON:MXCT) opened at 83.00 on Tuesday. MaxCyte has a 12 month low of GBX 75.00 and a 12 month high of GBX 86.38. The firm’s market capitalization is GBX 36.08 million. The firm’s 50-day moving average is GBX 84.50 and its 200 day moving average is GBX 82.01.

MaxCyte Company Profile

MaxCyte, Inc focuses on cell-based medicines. The Company’s cell modification technology, Flow electroporation, is used for discovery, development and manufacture of small molecule, biologic and cell-based therapeutics. The Company’s products include instruments, processing assemblies and insourcing services.

Receive News & Ratings for MaxCyte Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte Inc and related companies with's FREE daily email newsletter.